Scientific Conclave on Indian Pharmacopoeia (IP) 2026 Held in Haridwar
Dehradun ( Raghwendra Pratap Singh) : The Indian Pharmacopoeia Commission (IPC), an autonomous institution under the Ministry of Health and Family Welfare, Government of India, organized a Scientific Conclave and Interactive Session on Indian Pharmacopoeia (IP) 2026 “Strengthening Pharmaceutical Manufacturing through Pharmacopoeial Standards and Quality Compliance” at Haridwar yesterday, in collaboration with the Association of Devbhumi Pharma Industries (ADPI) and affiliated pharmaceutical manufacturing associations of Uttarakhand.
The conclave was organized with the objective of enhancing awareness on the provisions of IP 2026 and promoting quality compliance across the pharmaceutical manufacturing sector.
Uttarakhand is one of India’s leading pharmaceutical manufacturing hubs and has been among the states effectively utilizing the IP and Indian Pharmacopoeia Reference Substances for ensuring the quality, safety, and efficacy of medicines. Recognizing the state’s significant contribution to pharmaceutical manufacturing, the conclave was organized to further strengthen industry awareness, support compliance with pharmacopoeial requirements, and promote the consistent adoption of IP standards across the pharmaceutical sector, thereby providing handholding support to pharmaceutical manufacturers and other stakeholders in the state.
The conclave reaffirmed IPC’s commitment to fostering greater awareness of pharmacopoeial standards and strengthening collaboration with stakeholders to promote the manufacture of quality-assured medicines. The event concluded with a networking session, enabling continued dialogue among regulators, industry representatives, and scientific experts on advancing pharmaceutical quality and compliance in Uttarakhand and across the country.
